Allopurinol and Febuxostat for Gout: When They Are Used and What Patients Should Know

6 Jul

Black and white clinical image showing a gout treatment plan comparing allopurinol and febuxostat alongside serum urate and kidney function results.

When gout keeps coming back, the most important treatment decision is often not how to treat the next flare, but how to prevent the next one from happening at all. That usually means thinking about urate-lowering treatment — in other words, medication designed to bring the uric acid level down over time and keep it down.

For many patients, the two main long-term options are allopurinol and febuxostat. Both are used to lower uric acid. Both can be effective. But they are not interchangeable in every patient, and the choice between them should be based on the broader clinical picture, not simply on which drug happens to be prescribed first.

Why long-term gout treatment matters

Gout is often treated as a series of separate attacks, but recurrent flares usually mean there is an ongoing urate problem that has not yet been properly controlled. The aim of long-term urate-lowering treatment is not only to reduce the uric acid level on a blood test, but to prevent further flares, reduce crystal deposition, and lower the risk of joint damage or tophi over time.

That is why modern gout treatment is built around a treat-to-target approach. The goal is to reduce the serum urate below target and then keep it there consistently.

What do allopurinol and febuxostat actually do?

Both allopurinol and febuxostat are xanthine oxidase inhibitors. In simple terms, they work by reducing the body’s production of uric acid. If used properly and titrated carefully, both can lower urate levels enough to prevent further flares over time.

The key point is that these are preventive treatments, not flare treatments. They do not work by switching off pain immediately during an acute attack. They work by altering the long-term urate environment that allowed gout to develop in the first place.

Why allopurinol is often used first

Allopurinol is still the most familiar and most commonly used long-term urate-lowering drug in gout. It has been used for decades, most clinicians are comfortable with it, and it is effective for many patients when started at a low dose and then gradually increased to reach the urate target.

In practice, allopurinol is usually started at a low dose and then increased gradually. That often means starting at 100 mg once daily or less, and in some patients with chronic kidney disease a lower starting dose such as 50 mg once daily may be used. The dose is then titrated upwards step by step, guided by the serum urate level, kidney function and tolerability, rather than stopping at an arbitrary fixed dose.

Allopurinol is also the preferred first-line option in patients with major cardiovascular disease.

When febuxostat may be used instead

Febuxostat can be a very reasonable option in the right patient. It may be considered when:

allopurinol is not tolerated
allopurinol is contraindicated
allopurinol does not bring the urate down adequately despite appropriate dose titration
or there are practical reasons why febuxostat is a better fit for the individual patient

Febuxostat is also started at a low dose and then adjusted. In practice this commonly means starting at 80 mg once daily, with escalation if needed depending on urate response and the agreed treatment target.

This means the decision is not just about habit. It is about choosing the most appropriate drug for that particular patient.

The important cardiovascular point

This is the area where patients often need the clearest explanation.

The current UK position is more nuanced than many people realise. Allopurinol is preferred first-line in people with major cardiovascular disease. Febuxostat still has an important place, but it should be used more cautiously in patients with pre-existing major cardiovascular disease.

That does not mean febuxostat is unsafe for everyone, nor does it mean it cannot be used at all in patients with cardiovascular history. It means the decision should be made carefully, with proper consideration of cardiovascular history, gout severity, prior treatment response and alternative options.

This is one reason why a specialist review can be useful in more complex gout. The drug choice is not just about urate — it is also about the patient’s broader medical profile.

**What about HLA-B*58:01?**

Another important consideration with allopurinol is the HLA-B*58:01 genetic variant. This is associated with a significantly increased risk of severe allopurinol hypersensitivity reactions, including serious skin reactions.

That does not mean everyone needs genetic testing before starting allopurinol. In practice, testing is usually targeted rather than universal, and is most relevant in certain higher-risk ancestry groups (Han Chinese, Korean, Thai). If a patient is known to be HLA-B*58:01 positive, allopurinol is generally avoided and an alternative such as febuxostat may be considered.

This is another example of why gout treatment is not always as simple as choosing a familiar drug name. In some patients, the wider context materially changes what is safest.

Why starting low and treating to target matters

One of the commonest reasons long-term gout treatment fails is not that the drug is wrong, but that the treatment strategy is incomplete. Both allopurinol and febuxostat need to be used within a treat-to-target approach. That means checking the serum urate and adjusting treatment until the target is reached, rather than simply prescribing a fixed dose and hoping for the best.

Patients should also understand that starting urate-lowering treatment can paradoxically trigger gout flares in the short term, even though the treatment is the right long-term strategy. This happens because as urate levels begin to change, existing crystal deposits can become destabilised.

That is why prophylaxis is often recommended when allopurinol or febuxostat is started, most commonly with colchicine where appropriate. In practice, prophylaxis is often continued for 3–6 months, and sometimes longer if flares continue.

It is also worth noting that older teaching often advised waiting until a flare had completely settled before starting long-term urate-lowering treatment. In practice, urate-lowering treatment can be started during an acute flare if appropriate anti-inflammatory treatment is being given at the same time.

This is an important point for patients because an early flare after starting allopurinol or febuxostat does not mean the diagnosis is wrong and does not mean the treatment is failing. In fact, it can happen precisely because the treatment is beginning to work on the underlying urate burden.

It is also important not to stop allopurinol or febuxostat during an acute flare if they have already been started. If a flare occurs after treatment has been established, the urate-lowering drug should usually be continued and the flare treated in its own right. Stopping and restarting treatment tends to make the long-term process less effective and can add to confusion and further flares.

Patients also need to know that gout does not usually stop flaring the moment the urate target is reached. Even once the target uric acid level has been achieved, it can take 3–6 months, and sometimes longer in heavier crystal-burden disease, for flares to settle down properly as existing deposits gradually dissolve. This lag is one reason persistence matters, and why long-term treatment should not be judged too early.

What about tophi?

Tophi do not disappear quickly. Even when urate is brought below target, tophi usually shrink gradually over time rather than melting away within a few weeks.

Smaller or more recent deposits may improve over months, but larger and longer-standing tophi can take years to resolve fully. In patients with tophi or a heavier crystal burden, the urate target is often set lower and the time to improvement is usually longer. The aim is not only to prevent flares, but to help dissolve the existing crystal burden over time.

So for patients with tophi, long-term treatment needs to be understood as exactly that — long term.

What about diet?

Diet still matters in gout, but it is important to keep expectations realistic. Weight loss where appropriate, reducing excess alcohol, avoiding sugar-sweetened drinks, and moderating high-purine foods can all help lower uric acid to a degree. But in patients with recurrent gout attacks, diet alone usually has only a modest urate-lowering effect and is often not enough to prevent flares or dissolve a significant crystal burden. In that situation, medication is usually needed alongside sensible lifestyle measures, rather than instead of them.

Which drug is better?

For most patients, that is not the most helpful question.

The better question is: which drug is more appropriate in this clinical situation?

Allopurinol is often the default because it is familiar, effective and widely used. Febuxostat is useful when allopurinol is not tolerated, is unsuitable, or has not achieved the target despite sensible use. The choice becomes especially important when there is:

major cardiovascular disease
renal impairment
difficulty reaching target urate
frequent flares
tophi
or uncertainty about how long-term treatment should be structured

In other words, this is rarely a simple “good drug versus bad drug” decision. It is a patient-specific treatment decision.

Why expert assessment matters

This is one of the reasons a rheumatology review can help. The most useful long-term gout care is not just about prescribing a tablet. It is about:

confirming the diagnosis
understanding flare frequency and crystal burden
choosing the right urate-lowering strategy
interpreting cardiovascular and renal context properly
deciding when pharmacogenetic issues matter
and building a sensible long-term plan

Long-term success depends not only on choosing the right drug, but on staying on treatment consistently and adjusting it properly until the urate target is reached.

For some patients, especially those with recurrent flares, cardiovascular disease, treatment intolerance, persistent hyperuricaemia, tophi or uncertainty over which urate-lowering treatment is most appropriate, a private consultation can be helpful in making that plan clearer and more joined up.

The bottom line

Allopurinol and febuxostat are both important long-term treatments for gout. Both can lower uric acid effectively. Both can help prevent flares when used properly. But they are not chosen in a vacuum.

What matters most is not simply starting a urate-lowering drug, but using the right one, in the right way, with the right target and the right follow-up.

For patients, the key message is this: the right choice between allopurinol and febuxostat depends on the broader clinical picture. And the success of treatment depends not only on which drug is chosen, but on how carefully it is started, titrated, monitored, supported and continued over time.